Retroviral DNA Integration: Viral and Cellular Determinants of Target-Site Selection
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Retroviruses differ in their preferences for sites for viral DNA integration in the chromosomes of infected cells. Human immunodeficiency virus (HIV) integrates preferentially within active transcription units, whereas murine leukemia virus (MLV) integrates preferentially near transcription start sites and CpG islands. We investigated the viral determinants of integration-site selection using HIV chimeras with MLV genes substituted for their HIV counterparts. We found that transferring the MLV integrase (IN) coding region into HIV (to make HIVmIN) caused the hybrid to integrate with a specificity close to that of MLV. Addition of MLV gag (to make HIVmGagmIN) further increased the similarity of target-site selection to that of MLV. A chimeric virus with MLV Gag only (HIVmGag) displayed targeting preferences different from that of both HIV and MLV, further implicating Gag proteins in targeting as well as IN. We also report a genome-wide analysis indicating that MLV, but not HIV, favors integration near DNase I-hypersensitive sites (i.e., +/- 1 kb), and that HIVmIN and HIVmGagmIN also favored integration near these features. These findings reveal that IN is the principal viral determinant of integration specificity; they also reveal a new role for Gag-derived proteins, and strengthen models for integration targeting based on tethering of viral IN proteins to host proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Retroviral DNA Integration and the Chimeric Viruses Used in This Study (A) The DNA breaking and joining reactions mediating integration. Gray ovals represent integrase monomers, thick red lines represent viral DNA, black lines represent target DNA, and dots represent 5′ ends. (1) Linear blunt-ended viral cDNA is bound by integrase as part of the preintegration complex. (2) Integrase removes two nucleotides from the 3′ ends of the viral DNA, exposing recessed 3′ hydroxyl groups. (3) IN joins the recessed 3′ ends of viral DNA to the target DNA. (4) Unpairing of the target DNA between the joined ends of the viral DNA yields gaps in the target DNA. (5) DNA repair enzymes fill in the gaps. (6) The provirus is flanked by repeated segments of the target DNA. (B) Chimeric HIV derivatives containing segments of MLV. At the top is the HIV parent virus, with vpr and env inactivated and the puromycin resistance gene in place of nef. Following that are the chimeras, with substitutions of MLV gag gene segments (MA-, p12-, and CA-encoding regions) for HIV MA and CA, or substitution of MLV IN for HIV IN, or both [20,21]. The MLV genome (indicated by an asterisk) is shown for comparison. The MLV used in this study (MLVPuro) was an MLV-based vector (LPCX) encoding the puromycin resistance gene with Gag, Pol, and Env provided in trans. Although we refer to “Gag” in the text, we note that Gag is in fact a polyprotein which is cleaved into individual functional proteins by the action of the viral protease. (C) Target-sequence duplication lengths made by HIV, MLV, and the chimeric viruses. (D) Primary sequences at the site of integration for HIV, MLV, the chimeric viruses, and a previously published MLV dataset (MLV-Burgess). On the x-axis are the top strand positions surrounding the point of integration, which is represented by the blue arrow and line (between positions −1 and 0). For each dataset, the proportion of each base at a given location was divided by the proportion of that base in the matched random control set, such that a base with a y value >1 is present at an increased frequency, while a base with a y value <1 is present at a decreased frequency compared to random sites. A dashed red box surrounds the target sequence that is duplicated upon integration.](https://figures.cochat.ai/paper-figures/05f7d0bde8fb47e2ad42ba2f8a012e93/retroviral-dna-integration-viral-and-cellular-determinants-of-target-site-figure-1.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, proviral integration in the transcriptionally active regions could potentially favor expression of the viral genes, whereas integration in the transcriptionally silent regions (heterochromatin) may not be in favor of viral expression and may even force the virus to stay transcriptionally silent (Jordan et al. 2001, Lewinski et al. 2006, Einkauf et al. 2022, Teixeira et al. 2024).”
From Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication (2026) · cites this paper as Lewinski et al. 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, it is now becoming clearer that certain retroviruses like HIV tend to target gene-rich, transcriptionally active, euchromatic regions within the host’s chromosome to integrate.”
From Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication (2026) · cites this paper as Lewinski et al. 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, it has been suggested that Gag-derived protein(s), especially CA, plays an important role during retroviral integration.”
From Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication (2026) · cites this paper as Lewinski et al. 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence toward this has been drawn from experiments that have shown that mutations in HIV-1 CA and its interactions with cyclophilin do not inhibit viral integration but favor integration into the genomic regions that are not transcriptionally active, as opposed to wild-type virus typically integrating into the transcriptionally active regions (Lewinski et al. 2006, Schaller et al. 2011, Engelman”
From Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication (2026) · cites this paper as Lewinski et al. 2006
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The gammaretrovirus MLV exhibits preferential insertion near transcriptional start sites, while the lentivirus HIV preferentially inserts within transcriptional units.”
From Clinical use of lentiviral vectors (2018) · cites this paper as [17]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777 · cited 1×
“The integration frequency near CpG islands was then compared. CpG islands are regions rich in the CpG dinucleotide, which are undermethylated and frequently associated with gene regulatory regions [”
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.-L., Fraser, C. C., Cavazzana-Calvo, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200301163480314 · Cited by 1,867 · cited 1×
“The recent setbacks in human gene-therapy trials, in which a therapeutic retroviral vector integrated near the LMO-2 proto-oncogene and caused leukemia-like illness in three patients [1–3], have focused particular attention on the mechanisms responsible”
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Self-citationTranscription Start Regions in the Human Genome Are Favored Targets for MLV Integration
Wu, X., Li, Y., Crise, B., & Burgess, S. M. (2003) · Science · doi:10.1126/science.1083413 · Cited by 1,305 · cited 9×
“MLV strongly favors integration near CpG islands while HIV does not [11,14].”
Influential(2007) · Wiley eBooks · doi:10.1128/9781555817954 · Cited by 1,291
NUCLEASE HYPERSENSITIVE SITES IN CHROMATIN
Gross, D. S., & Garrard, W. T. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.001111 · Cited by 1,233
Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences
Mitchell, R. S., Beitzel, B. F., Schroder, A. R. W., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., & Bushman, F. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020234 · Cited by 976
Self-citationIntegration of murine leukemia virus DNA depends on mitosis.
Roe, T., Reynolds, T. C., Yu, G., & Brown, P. O. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05858.x · Cited by 921
Lewis, P. F., & Emerman, M. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.510-516.1994 · Cited by 797
Self-citation
Cited by
Items 201–300 of 415
Gabriel, R., Kutschera, I., Bartholomae, C. C., Kalle, C. V., & Schmidt, M. (2014) · Journal of Visualized Experiments · doi:10.3791/51543 · Cited by 21
Viral Hybrid Vectors for Somatic Integration - Are They the Better Solution?
Müther, N., Noske, N., & Ehrhardt, A. (2009) · Viruses · doi:10.3390/v1031295 · Cited by 21
Kim, S., Rusmevichientong, A., Dong, B., Remenyi, R., Silverman, R. H., & Chow, S. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010255 · Cited by 21
“transcription start sites and CpG islands) instead of transcription units as favored by HIV-1 [39].”
DNA methylation-mediated silencing of PU.1 in leukemia cells resistant to cell differentiation
Fernández-Nestosa, M. J., Monturus, E., Sánchez, Z., Torres, F. S., Fernández, A. F., Fraga, M. F., Hernández, P., Schvartzman, J. B., & Krimer, D. B. (2013) · SpringerPlus · doi:10.1186/2193-1801-2-392 · Cited by 20
Pais, G., Spinozzi, G., Cesana, D., Benedicenti, F., Albertini, A., Bernardo, M. E., Gentner, B., Montini, E., & Calabria, A. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac551 · Cited by 20
Couto, P. S., Stibbs, D. J., Rotondi, M. C., Takeuchi, Y., & Rafiq, Q. A. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12634-w · Cited by 20
“It was previously described that LV integration is not completely random and each class of retrovirus has its preferential insertion location (Lewinski et al. 2006; Ciuffi 2016; Milone and O’Doherty 2018).”
van Vollenstee, F. A., Jackson, C. S., Hoffmann, D., Potgieter, M., Durandt, C., & Pepper, M. S. (2016) · Cytotechnology · doi:10.1007/s10616-016-9945-6 · Cited by 20
“Integration of the lentiviral genomic material into the target cell genome is dependent on lentiviral integrase, the key determinant for gene-targeted integration specificity (Lewinski et al. 2006).”
HIV Latency: Present Knowledge and Future Directions
Contreras, X., Lenasi, T., & Peterlin, B. M. (2006) · Future Virology · doi:10.2217/17460794.1.6.733 · Cited by 20
“Three studies where T cells were infected without selection in vitro also demonstrated the integration into actively transcribed genes [16–18].”
Wen, Y., Liao, G., Pritchard, T., Zhao, T., Connelly, J. P., Pruett‐Miller, S. M., Blanc, V., Davidson, N. O., & Madison, B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777722 · Cited by 19
Qasim, W., Vink, C. A., & Thrasher, A. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.76 · Cited by 19
Retroviral vector interactions with hematopoietic cells
Everson, E. M., & Trobridge, G. D. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.07.010 · Cited by 19
Huston, M. W., Brugman, M. H., Horsman, S., Stubbs, A., van der Spek, P. J., & Wagemaker, G. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.037 · Cited by 18
“In general, we suggest that the nearest gene be whichever gene has its 5’ end closest to the IS, as viral integrations are known to alter expression of nearby genes via the long-terminal repeats (Wu et al. , 2003; Lewinski et al. , 2006) or the internal promoters (Modlich et al. , 2009).”
Maldarelli, F. M. (2015) · Journal of Virus Eradication · doi:10.1016/s2055-6640(20)30930-4 · Cited by 18
Boehm, D., Lam, V. L., Schnölzer, M., & Ott, M. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112234 · Cited by 18
Moiani, A., Miccio, A., Rizzi, E., Severgnini, M., Pellin, D., Suerth, J. D., Baum, C., Bellis, G. D., & Mavilio, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055721 · Cited by 18
“LEDGF/p75 is directly bound by the HIV integrase [26], a major viral determinant of target site selection [27].”
Retargeted Foamy Virus Vectors Integrate Less Frequently Near Proto-oncogenes
Hocum, J. D., Linde, I., Rae, D. T., Collins, C. P., Matern, L. K., & Trobridge, G. D. (2016) · Scientific Reports · doi:10.1038/srep36610 · Cited by 18
Su, K., Wang, D., Ye, J., Kim, Y. C., & Chow, S. A. (2009) · Methods · doi:10.1016/j.ymeth.2009.01.001 · Cited by 18
Ge, J., Lou, Z., Cui, H., Shang, L., & Harshey, R. M. (2011) · Journal of Biosciences · doi:10.1007/s12038-011-9108-z · Cited by 18
“…details of target selection have been studied in vitro for many individual TEs, in vivo studies are beginning to reveal the influence of host strategies in controlling transposition events (Lewinski et al. 2006; Beauregard et al. 2008; Brady et al. 2009; Parks et al. 2009; Guo and Levin 2010).”
A genome-wide map of adeno-associated virus–mediated human gene targeting
Deyle, D. R., Hansen, R. S., Cornea, A. M., Li, L. B., Burt, A., Alexander, I. E., Sandstrom, R. S., Stamatoyannopoulos, J. A., Wei, C., & Russell, D. W. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2895 · Cited by 18
Retroviral integration profiles: their determinants and implications for gene therapy
Lim, K. (2012) · BMB Reports · doi:10.5483/bmbrep.2012.45.4.207 · Cited by 17
“pattern that is different from that of HIV-1 or MLV, respectively; the introduction of sequences of the two MLV proteins results in an HIV-1 integration pattern closer to that of MLV (34).”
Dr.VIS: a database of human disease-related viral integration sites
Zhao, X., Liu, Q., Cai, Q., Li, Y., Xu, C., Li, Y., Li, Z., & Zhang, X. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr1142 · Cited by 17
“Moreover, viruses differ in their preferred insertion site (12).”
AAV-Mediated Gene Therapy for Atherosclerosis
Lehrke, M., & Lebherz, C. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0434-0 · Cited by 17
McAllister, R. G., Liu, J., Woods, M. W., Tom, S. K., Rupar, C. A., & Barr, S. D. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.39 · Cited by 17
Local features determine Ty3 targeting frequency at RNA polymerase III transcription start sites
Patterson, K., Shavarebi, F., Magnan, C., Chang, I., Qi, X., Baldi, P., Bilanchone, V., & Sandmeyer, S. B. (2019) · Genome Research · doi:10.1101/gr.240861.118 · Cited by 16
“For example, MLV IN interacts with bromodomain BET proteins, BRD2, BRD3, and BRD4 associated with promoter regions (Lewinski et al. 2006; Felice et al. 2009; De Rijck et al. 2013; Aiyer et al. 2014).”
Chromosomal tethering and proviral integration
Delelis, O., Zamborlini, A., Thierry, S., & Saïb, A. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.08.005 · Cited by 15
Polouliakh, N. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00007 · Cited by 15
A Profile of Native Integration Sites Used by φC31 Integrase in the Bovine Genome
Qu, L., Ma, Q., Zhou, Z., Ma, H., Huang, Y., Huang, S., Zeng, F., & Zeng, Y. (2012) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.03.004 · Cited by 14
“This is very different from retroviral vectors, which tend to integrate in proximity to transcriptional start sites (Lewinski et al., 2006).”
Desimmie, B. A., Demeulemeester, J., Christ, F., & Debyser, Z. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.10.002 · Cited by 14
Host Cell Factors and HIV-1 Integration
Engelman, A. (2007) · Future HIV Therapy · doi:10.2217/17469600.1.4.415 · Cited by 14
Interactions of Host Proteins with the Murine Leukemia Virus Integrase
Studamire, B., & Goff, S. P. (2010) · Viruses · doi:10.3390/v2051110 · Cited by 14
“HIV-1 genome, the integration patterns observed were similar to those observed for MoMLV [57].”
Inayoshi, Y., Okino, Y., Miyake, K., Mizutani, A., Yamamoto-Kishikawa, J., Kinoshita, Y., Morimoto, Y., Imamura, K., Morshed, M., Kono, K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02681-09 · Cited by 14
“IN is supposed to be the principal viral determinant of the integration specificity, probably through tethering to cellular proteins bound near preferred genomic regions (30).”
Weiser, K. C., Liu, B., Hansen, G. M., Skapura, D. G., Hentges, K. E., Yarlagadda, S. P., Morse, H. C., & Justice, M. J. (2007) · Mammalian Genome · doi:10.1007/s00335-007-9060-2 · Cited by 14
Evaluating the Genomic Parameters Governing rAAV-Mediated Homologous Recombination
Spector, L. P., Tiffany, M. R., Ferraro, N. M., Abell, N. S., Montgomery, S. B., & Kay, M. A. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.025 · Cited by 13
Suleman, S., Payne, A. M., Bowden, J., Alhaque, S., Zahn, M., Fawaz, S., Khalifa, M. S., Jobling, S., Hay, D. C., Franco, M., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00335-4 · Cited by 13
“LV are known to preferentially integrate into active transcription units in the host genome [4, 5, 7, 54] and various studies have shown insertional mutagenesis after HIV-1 mediated gene therapy [52].”
InfluentialRetroviral gene insertion in breast milk mediated lymphomagenesis
Chakraborty, J., Okonta, H., Bagalb, H. S., Lee, S. J., Fink, B., Rajesh, C., & Duggan, J. M. (2008) · Virology · doi:10.1016/j.virol.2008.04.008 · Cited by 13
“HIV can integrate at any time of the cell cycle, while MLV can integrate only after mitosis (Lewinski et al., 2006).”
InfluentialCharacterization of Equine Infectious Anemia Virus Integration in the Horse Genome
Liu, Q., Wang, X., Ma, J., He, X.-J., He, X.-J., & Zhou, J.-H. (2015) · Viruses · doi:10.3390/v7062769 · Cited by 13
“It is known that integration site selection in the human genome is largely determined by viral integrases and cellular factors that bind to and interact with integrases [57,58].”
Virus–Host Interactions in Retrovirus Integration
Engelman, A. N., & Maertens, G. N. (2018) · Retrovirus-Cell Interactions · doi:10.1016/b978-0-12-811185-7.00004-2 · Cited by 12
Santoni, F. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1214 · Cited by 12
Wegman‐Points, L., Teoh-Fitzgerald, M. L. T., Mao, G., Zhu, Y., Fath, M. A., Spitz, D. R., & Domann, F. E. (2014) · Redox Biology · doi:10.1016/j.redox.2014.06.006 · Cited by 12
Salamango, D. J., Evans, D. A. P., Baluyot, M. F., Furlong, J. N., & Johnson, M. C. (2013) · Journal of Virology · doi:10.1128/jvi.02524-13 · Cited by 12
Soto, M. J., Peña, Á., & Vallejo, F. G. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0182 · Cited by 12
Saito, S., Hosomichi, K., Yamanaka, M. P., Mizutani, T., Takeshima, S., & Aida, Y. (2022) · Retrovirology · doi:10.1186/s12977-022-00609-0 · Cited by 11
So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research
Kleinman, A. J., Pandrea, I., & Apetrei, C. (2022) · Viruses · doi:10.3390/v14010135 · Cited by 11
A prospective on drug abuse-associated epigenetics and HIV-1 replication
Pandhare, J., & Dash, C. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.10.005 · Cited by 11
Sleeping Beauty transposon vectors for therapeutic applications: advances and challenges
Narayanavari, S. A., & Izsvák, Z. (2017) · Cell and Gene Therapy Insights · doi:10.18609/cgti.2017.014 · Cited by 11
Applications of DNA integrating elements: Facing the bias bully
de Jong, J., Wessels, L. F. A., van Lohuizen, M., de Ridder, J., & Akhtar, W. (2014) · Mobile Genetic Elements · doi:10.4161/2159256x.2014.992694 · Cited by 11
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
Gene Therapy Applications for Fracture Repair
Cassandra, A., Donna, D., & Charles, H. (2011) · InTech eBooks · doi:10.5772/18499 · Cited by 10
Host Factors in Retroviral Integration and the Selection of Integration Target Sites
Craigie, R., & Bushman, F. D. (2015) · ASM Press eBooks · doi:10.1128/9781555819217.ch45 · Cited by 10
Self-citationLentiviral Vector Promoter is Decisive for Aberrant Transcript Formation
Scholz, S., Fronza, R., Bartholomae, C. C., Cesana, D., Montini, E., Kalle, C. V., Gil-Fariña, I., & Schmidt, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.162 · Cited by 10
“Amajordeterminantherein is the genus of the parental virus with its respective integrase.(9) Gammaretrovirus-derived vectors favor transcription start sites and active regulatory elements, whereas lentiviral vectors prefer gene-coding regions of actively transcribed genes.”
HIV-1 Integrase Drug Discovery Comes of Age
Demeulemeester, J., Maeyer, M. D., & Debyser, Z. (2013) · Topics in medicinal chemistry · doi:10.1007/7355_2013_33 · Cited by 9
de Freitas, M. C. C., Fontes, A. M., Fernandes, A. D. C., Picanço‐Castro, V., Russo, E. M. D. S., & Covas, D. T. (2014) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2014.03.002 · Cited by 9
Malignancies after Chimeric Antigen Receptor T Cell Therapy
Mohty, R., Halwani, A., Badar, T., Alkhateeb, H. B., Shah, M. V., Qin, H., & Kharfan‐Dabaja, M. A. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.06.001 · Cited by 8
Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors
Zheng, Y., Huang, J., Xu, Y., & Luo, H. (2024) · MedComm – Future Medicine · doi:10.1002/mef2.79 · Cited by 8
Zorina, A. I., Zorin, V. L., Isaev, A. A., Kudlay, D. A., Manturova, N., Ustugov, A., & Kopnin, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910270 · Cited by 8
“Osborn M. et al. (2013) first achieved up to 2% of genetic correction by means of the TALEN-mediated HDR [130] using DFs obtained from RDEB patients, which were subsequently reprogrammed into iPSCs.”
Pellaers, E., Bhat, A., Christ, F., & Debyser, Z. (2022) · Viruses · doi:10.3390/v15010032 · Cited by 8
“The fact that MLV IN and Gag can redirect HIV integration suggests that these may be determinants of MLV integration site selection as well [59] (Table 1).”
InfluentialTransgene Site-Specific Integration: Problems and Solutions
Bire, S., & Rouleux‐Bonnin, F. (2012) · Topics in current genetics · doi:10.1007/978-94-007-4531-5_1 · Cited by 8
Gammaretroviral Vector Integration Occurs Overwhelmingly Within and Near DNase Hypersensitive Sites
Liu, M., Li, C. L., Stamatoyannopoulos, G., Dorschner, M. O., Humbert, R., Stamatoyannopoulos, J. A., & Emery, D. W. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.177 · Cited by 8
Baum, C., Schambach, A., Modlich, U., & Thrasher, A. J. (2007) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-007-0385-5 · Cited by 8
“DNAse-I-hypersensitive Stellen, die regulatorischen Genbereichen entsprechen [50].”
Pseudotyped Viruses for Retroviruses
Solomon, M., & Liang, C. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-99-0113-5_4 · Cited by 7
Alternative Splicing Caused by Lentiviral Integration in the Human Genome
Moiani, A., & Mavilio, F. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00008-9 · Cited by 7
High-Throughput Mapping and Clonal Quantification of Retroviral Integration Sites
Gillet, N. A., Melamed, A., & Bangham, C. R. M. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6872-5_10 · Cited by 7
“Concomitantly, the nucleotide sequence of the host DNA and interactions between the preintegration complex and specific host factors also bias the targeting of insertion [1, 2].”
Nombela, I., Michiels, M., Looveren, D. V., Marcelis, L., Ashkar, S. E., Belle, S. V., Bruggemans, A., Tousseyn, T., Schwaller, J., Christ, F., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01478-22 · Cited by 7
Mechanisms of Oncogenesis by Avian and Murine Retroviruses
BEEMON, K. L., & Rosenberg, N. E. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0016-5_27 · Cited by 7
Functional Characteristics of a Highly Specific Integrase Encoded by an LTR-Retrotransposon
Faye, B., Arnaud, F., Peyretaillade, É., Brasset, É., Dastugue, B., & Vaury, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003185 · Cited by 7
“Two reactions catalyzed by the integrases encoded by mammalian retroviruses have been well described: 1) the removal of two bases from the 39 end of each viral DNA strand, and 2) the covalent attachment of leaving recessed 39 hydroxyl groups at the viral DNA termini to protruding 59 phosphoryl ends of host cell DNA (f…”
HIV-1 Integration into Chromatin: New Insights and Future Perspectives
Lesbats, P., Lavigne, M., & Parissi, V. (2011) · Future Virology · doi:10.2217/fvl.11.84 · Cited by 7
Rosenberg, N. E. (2010) · Springer eBooks · doi:10.1007/978-0-387-09581-3_1 · Cited by 6
“The features that control these differences are not fully understood, but both IN and Gag play a role (Lewinski et al., 2006).”
Metais, J., Topp, S., Doty, R. T., Borate, B. R., Nguyen, A.-D., Wolfsberg, T. G., Abkowitz, J. L., & Dunbar, C. E. (2010) · Gene Therapy · doi:10.1038/gt.2010.24 · Cited by 6
Lessons from Viral Latency in T Cells: Manipulating HIV-1 Transcription by Sirna
Suzuki, K., & Kelleher, A. D. (2010) · HIV Therapy · doi:10.2217/hiv.10.1 · Cited by 6
Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication
Jehad, M. A., Ali, L. M., Pillai, V. N., Prabhu, S. G., Mustafa, F., & Rizvi, T. A. (2026) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuaf066 · Cited by 5
“…with cyclophilin do not inhibit viral integration but favor integration into the genomic regions that are not transcriptionally active, as opposed to wild-type virus typically integrating into the transcriptionally active regions (Lewinski et al. 2006 , Schaller et al. 2011 , Engelman 2021 ).”
Tang, P., Bo, D., Reyes, C., Papp, D., & Potter, J. (2023) · BioTechniques · doi:10.2144/btn-2023-0013 · Cited by 5
Leveraging Vector-Based Gene Disruptions to Enhance CAR T-Cell Effectiveness
de Oliveira, B. C., Bari, S. M. N., & Melenhorst, J. J. (2025) · Cancers · doi:10.3390/cancers17030383 · Cited by 5
Epigenetic Regulation of HIV-1 Persistence and Evolving Strategies for Virus Eradication
Dhamija, N., Rawat, P., & Mitra, D. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-4525-4_21 · Cited by 5
Nam, J.-S., Lee, J.-E., Lee, K.-H., Yang, Y., Kim, S.-H., Bae, G., Noh, H., & Lim, K. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.001 · Cited by 5
Chemoprotection by Transfer of Resistance Genes
Budak-Alpdoǧan, T., & Bertino, J. R. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-561-9_34 · Cited by 5
Bertolotti, R. (2009) · Gene Therapy and Regulation · doi:10.1142/s1568558609000102 · Cited by 5
Hematopoietic immortalizing function of the NKL‐subclass homeobox geneTLX1
Zweier, L., Hawley, T. S., Burkett, S. S., Ramezani, A., Riz, I., Adler, R. L., Hickstein, D. D., & Hawley, R. G. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20725 · Cited by 4
“and thus favored for retroviral integration (Lewinski et al., 2006).”
InfluentialWang, B., Zhang, X., & Zhao, Z. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.101 · Cited by 4
Dustin, T., & Grant, D. (2013) · InTech eBooks · doi:10.5772/52530 · Cited by 4
“Viral Gag and integrase proteins have been shown to interact with chromatin, affectively tethering the PIC to specific chromoso‐ mal regions, thus directing integration [57, 58].”
InfluentialFourth-generation gene editors: Integration-based genome engineering
Kincaid, A. E., Hewitt, A. W., & Rajendra, K. C. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201753 · Cited by 3
“75,76 Mobile group II introns: Targetrons Targetrons are gene editing tools that have derived from mobile group II introns and are naturally occurring, self-splicing RNA enzymes that can integrate its own cDNA into defined genomic sites via target-primed reverse transcription (TPRT).”
Suryawanshi, G. W., Arokium, H., Kim, S., Khamaikawin, W., Lin, S., Shimizu, S., Chupradit, K., Lee, Y., Xie, Y., Guan, X., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02601-5 · Cited by 3
Thangsunan, P., Wongsaipun, S., Kittiwachana, S., & Suree, N. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1580219 · Cited by 3
Modulation of chromatin by MARs and MAR binding oncogenic transcription factor SMAR1
Nakka, K. K., & Chattopadhyay, S. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0262-7 · Cited by 3
“Genome wide analysis revealed that approximately 11% of the MuLV proviral integration sites are flanked by DNaseI hypersensitive sites [59].”
Moneva, M. L. V., & Oropilla, C. T. (2024) · Education and human development · doi:10.5772/intechopen.114138 · Cited by 3
Liu, Q., Wang, X., Du, C., Lin, Y., Ma, J., Wang, Y., Zhou, J.-H., & Wang, X. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000918 · Cited by 3
“In addition, HIV-1 IN residue Ser119 was found to affect viral integration [44], and HIV-1 capsid (CA) protein also affects IS selection [45, 46].”
Viruses and Viral Infections in Developing Countries
Jovanović-Ćupić, S., Abubakar, M., Önal, A., Saleemi, M. K., Božović, A., & Krajnović, M. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.73768 · Cited by 3
Host proteins interacting with integrase of human immunodeficiency virus type 1
Gu, W.-G., & Yao, Z.-Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117254 · Cited by 2
Retroviral Integration Target Site Selection
Ciuffi, A., & Bushman, F. D. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch5 · Cited by 2
Self-citationRetroviral Infection of hES Cells Produces Random-like Integration Patterns
Lim, K. (2012) · Molecules and Cells · doi:10.1007/s10059-012-0038-x · Cited by 2
miRNA Lentiviral Vector Integration and Gene Targeting Efficacy in Cardiac Progenitors
Loperfido, M., Crippa, S., & Sampaolesi, M. (2012) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.s9-003 · Cited by 2
“On the other hand, insertion site selection during in vitro transduction could be driven by cellular mechanisms such as tethering of transcription factors (TF) to specific genomic regions according to the presence of TF binding sites [50] and seems dependent on cellular determinants as well as on vector design [51].”
Bagalb, H. S. (2008) · OhioLink ETD Center (Ohio Library and Information Network) · Cited by 2
Retroviral integration sites (RIS) mark cis-regulatory elements
Ng, C. E. L., Ito, Y., & Osato, M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.10.008 · Cited by 2
Müller, L., Milsom, M. D., & Williams, D. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7656-7_6 · Cited by 2
Philippe, S. (2007) · HAL · Cited by 2
Chéret, A. (2014) · theses.fr (ABES) · doi:10.70675/476201c0z519az47dfz9e6az9e7e63dc4e55 · Cited by 2
Retroviruses as Tools to Identify Oncogenes and Tumor Suppressor Genes
Neil, J. C., & Stewart, M. A. (2010) · Springer eBooks · doi:10.1007/978-0-387-09581-3_10 · Cited by 2
Reconstitution and Characterization of Human Endogenous Retrovirus-K
Lee, Y. N. (2010) · Digital Commons - RU (Rockefeller University) · doi:10.48496/38w4-yp24 · Cited by 2
The clinical challenges of lifetime HAART
Paredes, R., Sherer, R. D., & Clotet, B. (2008) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780199225859.003.0026 · Cited by 2
Gene editing approaches of microsatellite disorders : shortening expanded repeats
Poggi, L. (2020) · theses.fr (ABES) · doi:10.70675/741f0470z28a0z4c3bz9e75ze578bdc49074 · Cited by 2
Labarthe, L. (2020) · theses.fr (ABES) · doi:10.70675/8e0a6f66ze74dz497cz89b5z17639f9eff02 · Cited by 2
Metadata
- Authors
- Lewinski, M. K., Yamashita, M., Emerman, M., Ciuffi, A., Marshall, H., Crawford, G., Collins, F., Shinn, P., Leipzig, J., Hannenhalli, S., Berry, C. C., Ecker, J. R., & Bushman, F. D.
- Affiliations
- Salk Institute for Biological Studies (US)
- Fred Hutch Cancer Center (US)
- University of Pennsylvania (US)
- National Institutes of Health (US)
- University of California San Diego (US)
- Corresponding author
- Bushman, Frederic D
- ORCID
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2006-06-23
- Volume
- 2
- Issue
- 6
- Pages
- e60
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- PMC
- PMC1480600
- OpenAlex
- W1980869599
- Cited by
- 364
- References
- 46
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 3 · 2023: 5 · 2022: 16 · 2021: 5 · 2020: 9 · 2019: 11 · 2018: 7 · 2017: 18 · 2016: 21 · 2015: 15 · 2014: 26 · 2013: 25 · 2012: 32
- FWCI
- 10.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Pathogens (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- James B. Pendleton Charitable Trust
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R37AI030927, AI30927, R56AI030927, AI52845, AI 34786, R01AI034786, R01AI030927, R01AI052845)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- retroviral integration, target site selection, HIV, murine leukemia virus, integrase, Gag protein, chimeric viruses, DNase I hypersensitive sites, CpG islands, transcription start sites, host-virus interaction
- MeSH terms
- Attachment Sites, Microbiological, Binding Sites, Chimera, Cloning, Molecular, Deoxyribonuclease I, DNA, Viral, Glycosaminoglycans, HeLa Cells, HIV, Humans, Leukemia Virus, Murine, Puromycin, Retroviridae, Transcription Factors, Transduction, Genetic, Virus Integration, Gene Transfer Techniques, CpG Islands, Integrases, Transcription Initiation Site
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.